Ibrutinib versus temsirolimus : 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study
(2018) In Leukemia 32(8). p.1799-1803
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/00f00ed4-fead-45c3-9414-310f0cc12c71
- author
- organization
- publishing date
- 2018-08
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Leukemia
- volume
- 32
- issue
- 8
- pages
- 1799 - 1803
- publisher
- Nature Publishing Group
- external identifiers
-
- scopus:85044345230
- pmid:29572505
- ISSN
- 0887-6924
- DOI
- 10.1038/s41375-018-0023-2
- language
- English
- LU publication?
- yes
- id
- 00f00ed4-fead-45c3-9414-310f0cc12c71
- date added to LUP
- 2018-04-06 08:21:31
- date last changed
- 2024-02-13 20:06:21
@article{00f00ed4-fead-45c3-9414-310f0cc12c71, author = {{Rule, S. and Jurczak, W. and Jerkeman, M. and Rusconi, C. and Trneny, M. and Offner, F. and Caballero, D. and Joao, C. and Witzens-Harig, M. and Hess, G. and Bence-Bruckler, I. and Cho, S. G. and Thieblemont, C. and Zhou, W. and Henninger, T. and Goldberg, J. and Vermeulen, J. and Dreyling, M.}}, issn = {{0887-6924}}, language = {{eng}}, number = {{8}}, pages = {{1799--1803}}, publisher = {{Nature Publishing Group}}, series = {{Leukemia}}, title = {{Ibrutinib versus temsirolimus : 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study}}, url = {{http://dx.doi.org/10.1038/s41375-018-0023-2}}, doi = {{10.1038/s41375-018-0023-2}}, volume = {{32}}, year = {{2018}}, }